SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors monitor the critical upcoming launch of three BlueBird satellites on a SpaceX Falcon 9 rocket, which is widely viewed as a major derisking event for the company's commercial rollout. Community sentiment is deeply divided between long-term holders expressing optimism about the future of space-based cellular broadband and traders voicing frustration over the stock's recent price volatility amidst broader sector rotation.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is currently trending as investors react to the unveiling of new AR-focused smart glasses, with intense community debate over the product's high price point and the company's long-term pivot toward hardware. While some participants argue that the technology and extensive patent portfolio provide significant future value, many shareholders are expressing frustration with management and calling for a shift in leadership or a change in corporate strategy.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is currently facing significant downward pressure and extreme volatility as investors express frustration over its 52-week lows and decoupling from positive broader market sentiment. The community remains deeply divided, with many traders lamenting the stock's persistent sell-offs while others emphasize long-term conviction in XPeng's potential for physical AI and robotics to drive a future re-rating.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is gaining momentum as investors react to its rapidly expanding global autonomous fleet, strategic partnerships with major OEMs like Geely and GAC, and a $100 million share repurchase program. The community is actively discussing the company's valuation gap compared to Western competitors and closely monitoring its upcoming Q1 earnings report for signs of sustained revenue growth.

Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF

Tradr 2X Long ASTS Daily ETF

ASTX is trending as traders use the leveraged ETF to bet on upcoming SpaceX launch milestones and high-volatility price swings in ASTS. Community sentiment is deeply divided between aggressive bulls seeking amplified gains and cautious traders warning of the inherent decay and danger associated with daily leveraged products.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is seeing massive investor activity driven by a robust trading update that maintained strong guidance despite geopolitical disruptions and multiple contract wins in its SMR and defense divisions. The community is actively discussing the company's successful turnaround into a high-margin industrial power and debating the impact of long-term sector tailwinds against temporary macroeconomic pressures.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is driving intense market activity following a high-profile IPO and a successful Falcon 9 launch, fueling community debate over its massive valuation relative to current revenue. While bullish investors are focused on its potential as a dominant AI and orbital infrastructure player, bearish participants are sounding alarms regarding a low public float and impending share lockup expirations.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford Motor Co is experiencing strong bullish momentum, driven by community excitement surrounding its recent expansion into energy storage and grid-scale battery systems. Investors are actively discussing the stock's potential for a valuation rerating as they weigh the company's established manufacturing scale against the high-growth narrative of its new energy initiatives.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors debate the regulatory outlook for its Axpaxli wet AMD treatment, specifically whether the SOL-1 data is sufficient for FDA approval or if additional trials are required. The community is actively discussing potential M&A activity, institutional ownership levels, and the upcoming Investor Day event as key factors that may drive volatility.

Invesco CurrencyShares Euro Trust - Invesco CurrencyShares Euro Trust

Invesco CurrencyShares Euro Trust

Invesco CurrencyShares Euro Trust is actively monitored as traders navigate central bank policy divergences and heightened geopolitical tensions in the Middle East, while community discourse focuses on the Euro's reaction to shifting interest rate expectations and the broader strength of the U.S. Dollar. Market participants are scrutinizing technical indicators and macroeconomic data releases for signals on potential trend reversals for the EUR/USD pair.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Add Myriad Genetics Stock to Your Portfolio Right Now?

MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.

Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026 

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock

MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.

Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh

Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.

MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans

Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.

Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)

Myriad (MYGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock

Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock...

TD Cowen Lowers Myriad Genetics (NASDAQ:MYGN) Price Target to $6.00

TD Cowen decreased their target price on Myriad Genetics from $7.00 to $6.00 and set a "hold" rating for the company in a research note on Wednesday...

Myriad Genetics (NASDAQ:MYGN) Given New $5.50 Price Target at Wells Fargo & Company

Wells Fargo & Company dropped their target price on Myriad Genetics from $6.00 to $5.50 and set an "equal weight" rating for the company in a report on Wednesday...

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.06	--	--	N/A
Q1 '26	-$0.07	-$0.09	-32.30%	MISSED
Q4 '25	-$0.01	$0.04	367.97%	BEAT
Q3 '25	-$0.01	$0.00	100.00%	BEAT
Q2 '25	-$0.01	$0.05	742.59%	BEAT

MYGNMyriad Genetics, Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest MYGN News